Integrum welcomes new board members
Integrum AB (publ), ticker INTEG, the medical technology company that provides the bone-anchored OPRA implant system to amputees, welcomes the new board members Kristofer Westergren and Anette Lindqvist elected on the Extra General Meeting.
Kristofer Westergren represents a group of major private shareholders in Integrum AB. He has followed the company closely for several years and thus has extensive knowledge of the business.
"Integrum has a strong market position and a large untapped potential that, for various reasons, is not reflected in today's valuation. I look forward to an active board work with a focus on increasing transparency towards the stock market and creating greater value for shareholders - and not least to contribute to Integrum's implant system reaching as many people in need as possible", says Kristofer Westergren.
Kristofer Westergren has extensive experience from the stock market as an investor and financial advisor to company managements in listed companies. He has founded and invested in several growth companies, and he has worked on the board of directors with operational improvements, value-creating acquisitions and company sales such as Sharkmob AB, KitchenTime Group AB and Corpura Fondkommission AB.
Anette Lindqvist holds a degree in Business Administration from the Gothenburg School of Economics and Executive Independent Courses from Harvard Business School in Boston and the Indian Institute of Management in Bangalore. With over 30 years of experience in the life science sector, she has held several senior positions in business development and senior positions in finance at companies such as AstraZeneca Plc., SOBI, Getinge and Mölnlycke Healthcare. She has also been active in GU Ventures and Chalmers. Anette is the founder of Lynton Management AB. Currently, she is the Deputy CEO and Chairman of the Board of both Lynton Management AB and Bueneman Medic AB. She is also the CFO at Xbrane Biopharma.
After the Extra General Meeting the Board of Directors in Integrum consists of the Chairman of the Board Bengt Sjöholm and the board members Rickard Brånemark, Karin Wingstrand, Cecilia Wikström, Andrew Christensen, Scott Flora, Anette Lindqvist and Kristofer Westergren.
For more information, please contact Jörgen Svanström, CFO Integrum, Jorgen.svanstrom@integrum.se.
Certified Adviser
Carnegie Investment Bank AB (publ) is Certified Adviser.
About Integrum
Integrum is a publicly traded company (Nasdaq First North Growth Market: INTEG B) based outside of Gothenburg, Sweden, with a U.S. subsidiary in San Francisco. Since 1990, its OPRA® Implant System has helped improve the quality of life for hundreds of people who are amputees by directly attaching a prosthesis to the bone and musculoskeletal system, therefore avoiding the need for a socket. Based on osseointegration, the bone-anchored implant system offers a range of benefits, including improved mobility and function, enhanced comfort, reduced pressure, a stable attachment and more. The OPRA® Implant System was approved by the U.S. Food and Drug Administration (FDA) in 2020 and is the only FDA-approved bone-anchored implant system specifically designed for use in amputees available in the U.S. Today, Integrum continues to perform research and develop custom-made medical device solutions in close collaboration with scientists and clinicians. To learn more, please visit https://integrum.se/. OPRA® Implant System is a registered trademark in the European Union.